Drugging the Angiogenic Axis: Novel Development Opportunity
The cross-pollination of therapeutic concepts between different medical fields is a powerful engine for innovation (Table). This path is well-trodden; cornerstone therapies in rheumatology, such as methotrexate and rituximab, were first developed and utilized in oncology before finding profound success in treating autoimmune diseases.
A novel agent in t…
Keep reading with a 7-day free trial
Subscribe to Drug Development Executive to keep reading this post and get 7 days of free access to the full post archives.